Company: BIAF
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023405
Chunk: 19

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 8
Chunk 19
---
. In the U.S., drugs,
biological products, and medical devices are regulated by the Federal Food, Drug, and Cosmetic Act (“FDCA”), which is administered
by the Food and Drug Administration (“FDA”) and the Centers for Medicare & Medicaid Services (“CMS”). The
Company has not yet obtained marketing authorization from the FDA but is able to market its CyPath® Lung test as a laboratory
developed test (“LDT”) sold by our wholly owned subsidiary PPLS, a clinical pathology laboratory accredited by the College
of American Pathologists (“CAP”) and certified under the Clinical Laboratory Improvement Amendments (“CLIA”).

Note
3. ACCOUNTS AND OTHER RECEIVABLES, NET

The
following is a summary of accounts receivables and other receivables:

SCHEDULE OF ACCOUNTS AND OTHER RECEIVABLES

    September 30,
                                                                                2025  
    December 31,
                                                                                2024 
  
    Patient service fees 
    $235,403  
    $915,488 
  
    Histology service fees 
     167,000  
     190,648 
  
    Medical director fees 
     19,444  
     5,194 
  
    Other receivables 
     27,143  
     27,874 
  
    Total accounts and other receivables, net 
    $448,990  
    $1,139,204 

Note
4. PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid
expenses and other current assets are summarized below:

SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS

    September 30,
                                                                                2025  
    December 31,
                                                                                2024 

    Prepaid insurance 
    $224,211  
    $248,364 
  
    Legal and professional 
     45,670  
     27,448 
  
    Other 
     190,306  
     147,183 
  
    Total prepaid expenses and other current assets 
    $460,187  
    $422,995 

Note
5. PROPERTY AND EQUIPMENT, NET

Property
and equipment are summarized below:

SCHEDULE OF PROPERTY AND EQUIPMENT 

    September 30,
                                                                                2025  
    December 31,
                                                                                2024 

    Lab equipment 
    $679,995  
    $662,747 
  
    Computers